188 related articles for article (PubMed ID: 28156019)
21. Angiogenesis drives psoriasis pathogenesis.
Heidenreich R; Röcken M; Ghoreschi K
Int J Exp Pathol; 2009 Jun; 90(3):232-48. PubMed ID: 19563608
[TBL] [Abstract][Full Text] [Related]
22. Differential expression of the angiogenesis growth factors in psoriasis vulgaris.
Liew SC; Das-Gupta E; Chakravarthi S; Wong SF; Lee N; Safdar N; Jamil A
BMC Res Notes; 2012 Jul; 5():201. PubMed ID: 22537619
[TBL] [Abstract][Full Text] [Related]
23. Gambogic acid exhibits anti-psoriatic efficacy through inhibition of angiogenesis and inflammation.
Wen J; Pei H; Wang X; Xie C; Li S; Huang L; Qiu N; Wang W; Cheng X; Chen L
J Dermatol Sci; 2014 Jun; 74(3):242-50. PubMed ID: 24685902
[TBL] [Abstract][Full Text] [Related]
24. Angiogenesis: the new potential target for the therapy of psoriasis?
Heidenreich R; Röcken M; Ghoreschi K
Drug News Perspect; 2008 Mar; 21(2):97-105. PubMed ID: 18389101
[TBL] [Abstract][Full Text] [Related]
25. Notch-1 mediates endothelial cell activation and invasion in psoriasis.
Rooney P; Connolly M; Gao W; McCormick J; Biniecka M; Sullivan O; Kirby B; Sweeney C; Molloy E; Markham T; Fearon U; Veale DJ
Exp Dermatol; 2014 Feb; 23(2):113-8. PubMed ID: 24330353
[TBL] [Abstract][Full Text] [Related]
26. A disintegrin and metalloprotease 10 is a novel mediator of vascular endothelial growth factor-induced endothelial cell function in angiogenesis and is associated with atherosclerosis.
Donners MM; Wolfs IM; Olieslagers S; Mohammadi-Motahhari Z; Tchaikovski V; Heeneman S; van Buul JD; Caolo V; Molin DG; Post MJ; Waltenberger J
Arterioscler Thromb Vasc Biol; 2010 Nov; 30(11):2188-95. PubMed ID: 20814017
[TBL] [Abstract][Full Text] [Related]
27. Role of Angiogenic and Inflammatory Signal Pathways in Psoriasis.
Man XY; Zheng M
J Investig Dermatol Symp Proc; 2015 Jul; 17(1):43-5. PubMed ID: 26067321
[No Abstract] [Full Text] [Related]
28. Vascular endothelial growth factor (VEGF), mast cells and inflammation.
Shaik-Dasthagirisaheb YB; Varvara G; Murmura G; Saggini A; Potalivo G; Caraffa A; Antinolfi P; Tete' S; Tripodi D; Conti F; Cianchetti E; Toniato E; Rosati M; Conti P; Speranza L; Pantalone A; Saggini R; Theoharides TC; Pandolfi F
Int J Immunopathol Pharmacol; 2013; 26(2):327-35. PubMed ID: 23755748
[TBL] [Abstract][Full Text] [Related]
29. Antivascular endothelial growth factor-A therapy: a novel personalized treatment approach for psoriasis.
Luengas-Martinez A; Paus R; Young HS
Br J Dermatol; 2022 May; 186(5):782-791. PubMed ID: 34878645
[TBL] [Abstract][Full Text] [Related]
30. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
31. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
32. VEGF is likely a key factor in the link between inflammation and angiogenesis in psoriasis: results of an immunohistochemical study.
Simonetti O; Lucarini G; Goteri G; Zizzi A; Biagini G; Lo Muzio L; Offidani A
Int J Immunopathol Pharmacol; 2006; 19(4):751-60. PubMed ID: 17166397
[TBL] [Abstract][Full Text] [Related]
33. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis.
Young HS; Summers AM; Read IR; Fairhurst DA; Plant DJ; Campalani E; Smith CH; Barker JN; Detmar MJ; Brenchley PE; Griffiths CE
J Invest Dermatol; 2006 Feb; 126(2):453-9. PubMed ID: 16385345
[TBL] [Abstract][Full Text] [Related]
34. Assessing the Association between Psoriasis and Cardiovascular Ischemia: An Investigation of Vascular Endothelial Growth Factor, Cutaneous Angiogenesis, and Arterial Stiffness.
Mohta A; Mohta A; Ghiya BC
Indian Dermatol Online J; 2023; 14(5):653-657. PubMed ID: 37727549
[TBL] [Abstract][Full Text] [Related]
35. Correlation of expression of STAT3, VEGF and differentiation of Th17 cells in psoriasis vulgaris of guinea pig.
Zheng XF; Sun YD; Liu XY
Asian Pac J Trop Med; 2014 Apr; 7(4):313-6. PubMed ID: 24507689
[TBL] [Abstract][Full Text] [Related]
36. Ginsenoside Rh2 Suppresses Neovascularization in Xenograft Psoriasis Model.
Zhou J; Gao Y; Yi X; Ding Y
Cell Physiol Biochem; 2015; 36(3):980-7. PubMed ID: 26087848
[TBL] [Abstract][Full Text] [Related]
37. Vascular endothelial growth factor and the regulation of angiogenesis.
Ferrara N
Recent Prog Horm Res; 2000; 55():15-35; discussion 35-6. PubMed ID: 11036931
[TBL] [Abstract][Full Text] [Related]
38. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J
Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666
[TBL] [Abstract][Full Text] [Related]
39. Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats.
Coch L; Mejias M; Berzigotti A; Garcia-Pras E; Gallego J; Bosch J; Mendez R; Fernandez M
Hepatology; 2014 Aug; 60(2):633-47. PubMed ID: 24390792
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis.
Manetti M; Guiducci S; Romano E; Ceccarelli C; Bellando-Randone S; Conforti ML; Ibba-Manneschi L; Matucci-Cerinic M
Circ Res; 2011 Jul; 109(3):e14-26. PubMed ID: 21636803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
